Cancer drug shows promise targeting genetic weakness in some tumors, comments Virginia Tech expert
Virginia TechIn an invited commentary, Kathleen Mulvaney, assistant professor with the Fralin Biomedical Research Institute at VTC, talks about the potential of a new drug that has shown early promise in clinical trials for solid tumors by killing cancer cells that lack specific tumor suppressor genes.